Find comprehensive information on Prostate Cancer with Metastasis, including clinical documentation, medical coding (ICD-10, ICD-11, SNOMED CT), staging (TNM), treatment options, and healthcare guidelines. Learn about bone metastasis, lymph node involvement, and distant metastases in prostate cancer. Explore resources for diagnosis, prognosis, and management of metastatic prostate cancer for healthcare professionals, patients, and caregivers.
Also known as
Malignant neoplasm of prostate
Cancer originating in the prostate gland.
Secondary malignant neoplasms of other sites
Cancer that has spread from the original site to other parts of the body.
Personal history of malignant neoplasm
Documentation of a past diagnosis of cancer, now resolved or in remission.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the prostate cancer documented as metastatic?
When to use each related code
| Description |
|---|
| Prostate cancer with metastasis |
| Localized prostate cancer |
| Prostate cancer, unspecified |
Insufficient documentation of specific metastasis site(s) leading to inaccurate coding and potential underpayment. Impacts CDI, medical coding audits, and compliance.
Miscoding prostate cancer that metastasized TO the prostate AS primary prostate cancer. Affects accurate reporting, reimbursement, and healthcare compliance audits.
Lack of clear documentation regarding lymph node involvement (N stage) impacting accurate staging, medical coding, and subsequent treatment planning and compliance.
Prostate cancer with metastasis has been confirmed in this patient. Presenting symptoms include persistent bone pain, fatigue, and weight loss. Initial evaluation revealed elevated prostate-specific antigen (PSA) levels exceeding 20 ngmL. Digital rectal examination (DRE) demonstrated an enlarged, nodular prostate. Subsequent imaging studies, including a bone scan and pelvic MRI, revealed metastatic lesions consistent with prostate cancer spread to the bone. Biopsy of the prostate gland confirmed the diagnosis of adenocarcinoma of the prostate, Gleason score 8 (4+4). Staging workup, including CT of the abdomen and pelvis, showed no evidence of visceral metastasis. The patient's performance status is currently ECOG 1. Treatment options including androgen deprivation therapy (ADT), chemotherapy, radiation therapy, and clinical trials were discussed with the patient. Considering the patient's age, overall health status, and extent of disease, a treatment plan consisting of androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) agonists was initiated. Patient education regarding disease progression, potential treatment side effects including hot flashes, erectile dysfunction, and osteoporosis, and follow-up care was provided. Referral to medical oncology and radiation oncology for further evaluation and consideration of additional treatment modalities has been made. Continued monitoring of PSA levels, imaging studies, and symptom management will be essential. The patient understands the diagnosis, prognosis, and treatment plan and is agreeable with the recommended course of action. The patient will follow up in two weeks to assess treatment response and manage any potential side effects. ICD-10 code C61 Malignant neoplasm of prostate and C79.51 Secondary malignant neoplasm of bone and bone marrow has been assigned.